Physician profile
Luis E Padula
NPI 1821093154
$13,962.04
in general payments reported to CMS, 2019-2025
28 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,488 · 2020: $1,349 · 2021: $2,700 · 2022: $1,559 · 2023: $906 · 2024: $833 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.32 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $4,231.67 | 2019-2022 | |
| Medtronic, INC. | $3,247.10 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Endurant Iis |
| Abbott Laboratories | $2,460.73 | 2020-2025 | Esprit, Jot Dx, Perclose Proglide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.02 | 2019-2022 | |
| Medtronic Vascular, INC. | $600.87 | 2020 | |
| Abiomed | $454.52 | 2019-2021 | |
| Boston Scientific Corporation | $269.71 | 2021-2023 | |
| Cvrx, INC. | $251.78 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $234.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $202.61 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $199.97 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $194.21 | 2019-2025 | Lokelma |
| Siemens Medical Solutions USA, INC. | $165.65 | 2019 | |
| Amgen INC. | $151.37 | 2019-2022 | |
| Biotronik INC. | $136.13 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $133.33 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $122.34 | 2021-2024 | Camzyos |
| Edwards Lifesciences Corporation | $51.35 | 2020 | |
| Preventice Services, LLC | $38.23 | 2020 | |
| Bridgebio Pharma, INC. | $38.01 | 2025 | Attruby |
| Irhythm Technologies, INC. | $34.40 | 2019 | |
| Amarin Pharma, INC. | $30.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $30.50 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Lantheus Medical Imaging, INC. | $19.50 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.83 | 2019 | |
| Gilead Sciences, INC. | $13.61 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Padula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.